

7. References

1. Organization WH. Global tuberculosis report 2016. *World Health Organization* 2016. ISBN 9 789241 565394.
2. Daniel TM. The history of tuberculosis. *Respiratory medicine*. 2006;100(11):1862-1870.
3. Keshavjee S, Farmer PE. Tuberculosis, drug resistance, and the history of modern medicine. *The New England Journal of Medicine*. 2012;367(10):931-936.
4. Monedero I, Caminero JA, Bhavaraju R, Sanchez-Montalva A. The changing landscape in drug resistant-tuberculosis: an analysis of recent advances. *Expert Review of Respiratory Medicine*. 2016;10(6):603-606.
5. Zumla A, Oliver M, Sharma V, Masham S, Herbert N. World TB Day 2016-advancing global tuberculosis control efforts. *The Lancet Infectious Diseases*. 2016;16(4):396-398.
6. Organization WH. Global tuberculosis report 2015: *World Health Organization*; 2015. ISBN: 9789241565059.
7. Zumla A, Davies P. Progress towards achieving global tuberculosis control: so near, yet so far. *The International Journal of Tuberculosis and Lung Disease*. 2016;20(3):285-286.
8. Kaufmann S, Evans TG, Hanekom WA. Tuberculosis vaccines: time for a global strategy. *Science Translational Medicine*. 2015;7(276):276fs8.
9. J Ahsan M, K Garg S, Vashistha B, Sharma P. Tuberculosis vaccines: hopes and hurdles. *Infectious Disorders Drug Targets*. 2013;13(5):318-321.
10. Knechel NA. Tuberculosis: pathophysiology, clinical features, and diagnosis. *Critical care nurse*. 2009;29(2):34-43.
11. Lin PL, Flynn JL. Understanding latent tuberculosis: a moving target. *The Journal of Immunology*. 2010;185(1):15-22.
12. Dai R, Wilson DJ, Geders TW, Aldrich CC, Finzel BC. Inhibition of *Mycobacterium tuberculosis* transaminase BioA by aryl hydrazines and hydrazides. *ChemBioChem*. 2014;15(4):575-586.
13. Dye C, Glaziou P, Floyd K, Raviglione M. Prospects for tuberculosis elimination. *Annual review of public health*. 2013;34:271-286.
14. Abu-Raddad LJ, Sabatelli L, Achterberg JT, Sugimoto JD, Longini IM, Dye C, Halloran ME. Epidemiological benefits of more-effective tuberculosis vaccines, drugs, and diagnostics. *Proceedings of the National Academy of Sciences*. 2009;106(33):13980-13985.
15. Menzies D, Al Jahdali H, Al Otaibi B. Recent developments in treatment of latent tuberculosis infection. *The Indian journal of medical research*. 2011;133(3):257-266.
16. Sterling TR, Villarino ME, Borisov AS, Shang N, Gordin F, Bliven-Sizemore E, Hackman J, Hamilton CD, Menzies D, Kerrigan A. Three months of rifapentine and isoniazid for latent tuberculosis infection. *New England Journal of Medicine*. 2011;365(23):2155-2166.
17. Martins M, Schelz Z, Martins A, Molnar J, Hajös G, Riedl Z, Viveiros M, Yalcin I, Aki-Sener E, Amaral L. *In vitro* and *ex vivo* activity of thioridazine derivatives against *Mycobacterium tuberculosis*. *International Journal of Antimicrobial Agents*. 2007;29(3):338-340.

18. Parrish NM, Dick JD, Bishai WR. Mechanisms of latency in *Mycobacterium tuberculosis*. *Trends in Microbiology*. 1998;6(3):107-112.
19. Organization WH. Multidrug and extensively drug-resistant TB: Global report on surveillance and response. *World Health Organization* 2010. ISBN: 978 92 4 159919 1.
20. Goletti D, Weissman D, Jackson RW, Graham N, Vlahov D, Klein RS, Munsiff SS, Ortona L, Cauda R, Fauci AS. Effect of *Mycobacterium tuberculosis* on HIV replication. Role of immune activation. *Journal of Immunology*. 1996;157(3):1271-1278.
21. Semvua HH, Kibiki GS, Kisanga ER, Boeree MJ, Burger DM, Aarnoutse R. Pharmacological interactions between rifampicin and antiretroviral drugs: challenges and research priorities for resource-limited settings. *Therapeutic Drug Monitoring*. 2015;37(1):22-32.
22. Blair HA, Scott LJ. Delamanid: A Review of Its Use in Patients with Multidrug-Resistant Tuberculosis. *Drugs*. 2015;75(1):91-100.
23. Somoskovi A, Bruderer V, Hömke R, Bloemberg GV, Böttger EC. A mutation associated with clofazimine and bedaquiline cross-resistance in MDR-TB following bedaquiline treatment. *European Respiratory Journal*. 2014:erj01429-2014.
24. Andries K, Vilellas C, Coeck N, Thys K, Gevers T, Vranckx L, Lounis N, de Jong BC, Koul A. Acquired Resistance of *Mycobacterium tuberculosis* to Bedaquiline. *PLoS ONE*. 2014;9(7):e102135.
25. Tillotson GS, Zinner SH. Paul Ehrlich, a prescient pioneer in the field of antimicrobial chemotherapy: what did he foresee a century ago?. *Expert Review of Anti-infective Therapy*. 2013;11(2):113-115.
26. Wainwright M, Crossley K. Methylene Blue—a therapeutic dye for all seasons? *Journal of Chemotherapy*. 2002;14(5):431-443.
27. Warman AJ, Rito TS, Fisher NE, Moss DM, Berry NG, O'Neill PM, Ward SA, Biagini GA. Antitubercular pharmacodynamics of phenothiazines. *Journal of Antimicrobial Chemotherapy*. 2013;68(4):869-880.
28. Boshoff HI, Myers TG, Copp BR, McNeil MR, Wilson MA, Barry CE. The transcriptional responses of *Mycobacterium tuberculosis* to inhibitors of metabolism novel insights into drug mechanisms of action. *Journal of Biological Chemistry*. 2004;279(38):40174-40184.
29. Kristiansen JE, Amaral L. The potential management of resistant infections with non-antibiotics. *Journal of Antimicrobial Chemotherapy*. 1997;40(3):319-327.
30. Amaral L, Kristiansen JE, Viveiros M, Atouguia J. Activity of phenothiazines against antibiotic-resistant *Mycobacterium tuberculosis*: a review supporting further studies that may elucidate the potential use of thioridazine as anti-tuberculosis therapy. *Journal of Antimicrobial Chemotherapy*. 2001;47(5):505-511.
31. Dunn E. Characterization of Alkyltriphenylphosphonium Cations and Their Interaction with Bacterial Cells: *University of Otago*; 2011. <http://hdl.handle.net/10523/2062>.
32. Kigonda EM, Njoroge M, Singh K, Njuguna N, Warner DF, Chibale K. Synthesis and synergistic antimycobacterial screening of chlorpromazine and its metabolites. *MedChemComm*. 2014;5(4):502-506.
33. Crowle AJ, Douvas GS, May MH. Chlorpromazine: A Drug Potentially Useful for Treating Mycobacterial Infections. *Chemotherapy*. 1992;38(6):410-419.

34. Kishore KK, Ramakanth G, Chandrasekhar N, Kishan P, Kumar CU, Usharani P. Thioridazine: a potential adjuvant in pharmacotherapy of drug resistant tuberculosis. *International Journal of Basic & Clinical Pharmacology* 2014;3(6):928-932.
35. Shahid S. Newer patents in antimycobacterial therapy. *Pharmaceutical Patent Analyst*. 2015;4(3):219-238.
36. Zhang Y, Amzel L. Tuberculosis drug targets. *Current Drug Targets*. 2002;3(2):131-154.
37. Thanacoody H. Thioridazine: resurrection as an antimicrobial agent? *British Journal of Clinical Pharmacology* 2007;64(5):566-574.
38. Amaral L, Kristiansen JE, Viveiros M, Atouguia J. Activity of phenothiazines against antibiotic-resistant *Mycobacterium tuberculosis*: a review supporting further studies that may elucidate the potential use of thioridazine as anti-tuberculosis therapy. *Journal of Antimicrobial Chemotherapy*. 2001;47(5):505-511.
39. Rodrigues L, Wagner D, Viveiros M, Sampaio D, Couto I, Vavra M, Kern WV, Amaral L. Thioridazine and chlorpromazine inhibition of ethidium bromide efflux in *Mycobacterium avium* and *Mycobacterium smegmatis*. *Journal of Antimicrobial Chemotherapy*. 2008;61(5):1076-1082.
40. Kristiansen JE, Dastidar SG, Palchoudhuri S, Sinha Roy D, Das S, Hendricks O, Christensen JB. Phenothiazines as a solution for multidrug resistant tuberculosis: From the origin to present. *International Microbiology*. 2015;18(1):1-12.
41. Gadre D, Talwar V, Gupta H, Murthy P. Effect of trifluoperazine, a potential drug for tuberculosis with psychotic disorders, on the growth of clinical isolates of drug resistant *Mycobacterium tuberculosis*. *International Clinical Psychopharmacology*. 1998;13(3):129-131.
42. Advani MJ, Siddiqui I, Sharma P, Reddy H. Activity of trifluoperazine against replicating, non-replicating and drug resistant *M. tuberculosis*. PLoS ONE. 2012;7(8):e44245.
43. Kristiansen JE, Vergmann B. The antibacterial effect of selected phenothiazines and thioxanthenes on slow-growing mycobacteria. *Acta Pathologica, Microbiologica, Et Immunologica Scandinavica. Section B*. 1986;94(6):393-398.
44. Dunn EA, Roxburgh M, Larsen L, Smith RA, McLellan AD, Heikal A, Murphy MP, Cook GM. Incorporation of triphenylphosphonium functionality improves the inhibitory properties of phenothiazine derivatives in *Mycobacterium tuberculosis*. *Bioorganic & Medicinal Chemistry*. 2014;22(19):5320-5328.
45. Duggal S, Kaur N, Duggal AK, Bhatia M. Phenothiazines: hope against MDR-TB. *Delhi Psychiatry Journal*. 2008;11(1):64-68.
46. Ritu S, Pushkal S, Srivastava S, Srivastava S. Synthesis and biological activity of 2-oxo-azetidine derivatives of phenothiazine. *Organic Communications*. 2011;4(2):42-51.
47. Ramprasad J, Nayak N, Dalimba U. Design of new phenothiazine-thiadiazole hybrids via molecular hybridization approach for the development of potent antitubercular agents. *European Journal of Medicinal Chemistry*. 2015;106:75-84.
48. Kigonde EM, Wasuna A, Warner DF, Chibale K. Pharmacologically active metabolites, combination screening and target identification-driven drug

- repositioning in antituberculosis drug discovery. *Bioorganic & Medicinal Chemistry*. 2014;22(16):4453-4461.
49. Addla D, Jallapally A, Gurram D, Yogeewari P, Sriram D, Kantevari S. Rational design, synthesis and antitubercular evaluation of novel 2-(trifluoromethyl) phenothiazine-[1, 2, 3] triazole hybrids. *Bioorganic & Medicinal Chemistry Letters*. 2014;24(1):233-236.
50. Seelam NS, S. P.; Prasanthi, S. Synthesis and antitubercular activity of some thiazolidinone derivatives incorporating with Phenothiazine moiety. *Heterocyclic Letters*. 2012;2(4):429-436.
51. Trivedi AR, Dholariya BH, Vakhariya CP, Dodiya DK, Ram HK, Kataria VB, Siddiqui AB, Shah VH. Synthesis and anti-tubercular evaluation of some novel pyrazolo [3, 4-d] pyrimidine derivatives. *Medicinal Chemistry Research*. 2012;21(8):1887-1891.
52. Rajasekaran A, Periasamy M, Venkatesan S. Synthesis, characterization and biological activity of some novel azetidiones. *Journal of Developmental Biology and Tissue Engineering*. 2010;2(1):5-13.
53. Salie S, Hsu N-J, Semenya D, Jardine A, Jacobs M. Novel non-neuroleptic phenothiazines inhibit *Mycobacterium tuberculosis* replication. *Journal of Antimicrobial Chemotherapy*. 2014;69(6):1551-1558.
54. Amani AM. Synthesis and biological activity of piperazine derivatives of phenothiazine. *Drug Research*. 2015;65(1):5-8.
55. He C-X, Meng H, Zhang X, Cui H-Q, Yin D-L. Synthesis and bio-evaluation of phenothiazine derivatives as new anti-tuberculosis agents. *Chinese Chemical Letters*. 2015;26(8):951-954.
56. Jardine MA, JACOBS M. Phenothiazine derivatives and their use against tuberculosis. Google Patents; 2014. WO2014080378A1.
57. Siddiqui AB, Trivedi AR, Kataria VB, Shah VH. 4, 5-Dihydro-1H-pyrazolo [3, 4-d] pyrimidine containing phenothiazines as antitubercular agents. *Bioorganic & Medicinal Chemistry Letters*. 2014;24(6):1493-1495.
58. Bate AB, Kalin JH, Fooksman EM, Amorose EL, Price CM, Williams HM, Rodig MJ, Mitchell MO, Cho SH, Wang Y, Franzblau SG. Synthesis and antitubercular activity of quaternized promazine and promethazine derivatives. *Bioorganic & Medicinal Chemistry Letters*. 2007;17(5):1346-1348.
59. Madrid PB, Polgar WE, Toll L, Tanga MJ. Synthesis and antitubercular activity of phenothiazines with reduced binding to dopamine and serotonin receptors. *Bioorganic & Medicinal Chemistry Letters*. 2007;17(11):3014-3017.
60. Joo LA. Method for the recovery of carbazole from coal tar fractions. Google Patents; 1968. US3407209A.
61. Chakraborty D, Barman B, Bose P. On the constitution of murrayanine, a carbazole derivative isolated from *Murraya koenigii* Spreng. *Tetrahedron*. 1965;21(2):681-685.
62. Zhang F-F, Gan L-L, Zhou C-H. Synthesis, antibacterial and antifungal activities of some carbazole derivatives. *Bioorganic & Medicinal Chemistry Letters*. 2010;20(6):1881-1884.
63. Rajakumar P, Sekar K, Shanmugaiah V, Mathivanan N. Synthesis of novel carbazole based macrocyclic amides as potential antimicrobial agents. *European Journal of Medicinal Chemistry*. 2009;44(7):3040-3045.
64. Saravanabhavan M, Sathya K, Puranik VG, Sekar M. Synthesis, spectroscopic characterization and structural investigations of new adduct compound of carbazole with picric acid: DNA binding and antimicrobial studies.

- Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy*. 2014;118:399-406.
65. Börger C, Brütting C, Julich-Gruner KK, Hesse R, Kumar VP, Kutz SK, Rönnefahrt M, Thomas C, Wan B, Franzblau SG. Anti-tuberculosis activity and structure-activity relationships of oxygenated tricyclic carbazole alkaloids and synthetic derivatives. *Bioorganic & medicinal chemistry*. 2017;25(22):6167-6174.
 66. Surineni G, Yogeewari P, Sriram D, Kantevari S. Rational design, synthesis and evaluation of novel-substituted 1, 2, 3-triazolylmethyl carbazoles as potent inhibitors of *Mycobacterium tuberculosis*. *Medicinal Chemistry Research*. 2015;24(3):1298-1309.
 67. Taj T, Kamble RR, Gireesh T, Hunnur RK, Margankop SB. One-pot synthesis of pyrazoline derivatised carbazoles as antitubercular, anticancer agents, their DNA cleavage and antioxidant activities. *European Journal of Medicinal Chemistry*. 2011;46(9):4366-4373.
 68. Guo S, Tipparaju SK, Pegan SD, Wan B, Mo S, Orjala J, Mesecar AD, Franzblau SG, Kozikowski AP. Natural product leads for drug discovery: isolation, synthesis and biological evaluation of 6-cyano-5-methoxyindolo [2, 3-a] carbazole based ligands as antibacterial agents. *Bioorganic & medicinal chemistry*. 2009;17(20):7126-7130.
 69. Zall A, Kieser D, Höttecke N, Naumann EC, Thomaszewski B, Schneider K, Steinbacher DT, Schubanel R, Masur S, Baumann K, Schmidt B. NSAID-derived γ -secretase modulation requires an acidic moiety on the carbazole scaffold. *Bioorganic & medicinal chemistry*. 2011;19(16):4903-4909.
 70. Thiratmatrakul S, Yenjai C, Waiwut P, Vajragupta O, Reubroycharoen P, Tohda M, Boonyarat C. Synthesis, biological evaluation and molecular modeling study of novel tacrine-carbazole hybrids as potential multifunctional agents for the treatment of Alzheimer's disease. *European Journal of Medicinal Chemistry*. 2014;75:21-30.
 71. Sun L, Wu Y, Liu Y, Chen X, Hu L. Novel carbazole sulfonamide derivatives of antitumor agent: Synthesis, antiproliferative activity and aqueous solubility. *Bioorganic & Medicinal Chemistry Letters*. 2017;27(2):261-265.
 72. Caruso A, Iacopetta D, Puoci F, Rita Cappello A, Saturnino C, Stefania Sinicropi M. Carbazole derivatives: a promising scenario for breast cancer treatment. *Mini reviews in medicinal chemistry*. 2016;16(8):630-643.
 73. Das K, Chakraborty D, Bose P. Antifungal activity of some constituents of *Murraya koenigii* spreng. *Cellular and Molecular Life Sciences*. 1965;21(6):340-342.
 74. Fisher LD. Carvedilol and the Food and Drug Administration (FDA) approval process: the FDA paradigm and reflections on hypothesis testing. *Controlled clinical trials*. 1999;20(1):16-39.
 75. Papich MG. An update on nonsteroidal anti-inflammatory drugs (NSAIDs) in small animals. *Veterinary Clinics of North America: Small Animal Practice*. 2008;38(6):1243-1266.
 76. Méjean A, Guillaume J-L, Strosberg AD. Carazolol: a potent, selective β_3 -adrenoceptor agonist. *European Journal of Pharmacology: Molecular Pharmacology*. 1995;291(3):359-366.
 77. Balbisi E. Frovatriptan succinate, a 5-HT_{1B/1D} receptor agonist for migraine. *International journal of clinical practice*. 2004;58(7):695-705.

78. Matveeva IA. Action of dimebon on histamine receptors. *Farmakologiya I Toksikologiya*. 1983;46(4):27-29.
79. Sabbagh MN, Shill HA. Latrepirdine, a potential novel treatment for Alzheimer's disease and Huntington's chorea. *Current Opinion in Investigational Drugs*. 2010;11(1):80-91.
80. Wood PL, McQuade PS. Ciclindole and flucindole: novel tetrahydrocarbazolamine neuroleptics. *Progress in Neuro-Psychopharmacology & Biological Psychiatry*. 1984;8(4-6):773-777.
81. Gilmore DL, Liu Y, Matsumoto RR. Review of the pharmacological and clinical profile of rimcazole. *CNS drug reviews*. 2004;10(1):1-22.
82. Kok YY, Mooi LY, Ahmad K, Sukari MA, Mat N, Rahmani M, Ali AM. Antitumour promoting activity and antioxidant properties of girinimbine isolated from the stem bark of *Murraya koenigii* S. *Molecules*. 2012;17(4):4651-4660.
83. Dineshkumar B, Mitra A, Mahadevappa M. Antidiabetic and hypolipidemic effects of mahanimbine (carbazole alkaloid) from *Murraya koenigii* (rutaceae) leaves. *International Journal of Phytomedicine*. 2010;2(1):22-30.
84. You H, Gadotti VM, Petrov RR, Zamponi GW, Diaz P. Functional characterization and analgesic effects of mixed cannabinoid receptor/T-type channel ligands. *Molecular Pain*. 2011;7:89-91.
85. Adebajo AC, Ayoola OF, Iwalewa EO, Akindahunsi AA, Omisore NO, Adewunmi CO, Adenowo TK. Anti-trichomonal, biochemical and toxicological activities of methanolic extract and some carbazole alkaloids isolated from the leaves of *Murraya koenigii* growing in Nigeria. *Phytomedicine*. 2006;13(4):246-254.
86. Sunthitikawinsakul A, Kongkathip N, Kongkathip B, Phonnakhu S, Daly JW, Spande TF, Nimit Y, Rochanaruangrai S. Coumarins and carbazoles from *Clausena excavata* exhibited antimycobacterial and antifungal activities. *Planta Medica*. 2003;69(02):155-157.
87. Ma C, Case RJ, Wang Y, Zhang H-J, Tan GT, Van Hung N, Cuong NM, Franzblau SG, Soejarto DD, Fong HH. Anti-tuberculosis constituents from the stem bark of *Micromelum hirsutum*. *Planta Medica*. 2005;71(03):261-267.
88. Maneerat W, Ritthiwigrom T, Cheenpracha S, Prawat U, Laphookhieo S. Clausenawallines A and B, two new dimeric carbazole alkaloids from the roots of *Clausena wallichii*. *Tetrahedron letters*. 2011;52(26):3303-3305.
89. Patpi SR, Pulipati L, Yogeewari P, Sriram D, Jain N, Sridhar B, Murthy R, Kalivendi SV, Kantevari S. Design, synthesis, and structure-activity correlations of novel dibenzo [b, d] furan, dibenzo [b, d] thiophene, and N-methylcarbazole clubbed 1, 2, 3-triazoles as potent inhibitors of *mycobacterium tuberculosis*. *Journal of medicinal chemistry*. 2012;55(8):3911-3922.
90. Surineni G, Yogeewari P, Sriram D, Kantevari S. Design and synthesis of novel carbazole tethered pyrrole derivatives as potent inhibitors of *Mycobacterium tuberculosis*. *Bioorganic & Medicinal Chemistry Letters*. 2015;25(3):485-491.
91. Shaikh MS, Palkar MB, Patel HM, Rane RA, Alwan WS, Shaikh MM, Shaikh IM, Hampannavar GA, Karpoornath R. Design and synthesis of novel carbazole-thiazoles as potential anti-mycobacterial agents using a molecular hybridization approach. *RSC Advances*. 2014;4(107):62308-62320.

92. Balamurali R, Prasad KR. Synthesis, characterization and pharmacological activities of 5, 6, 11, 12-tetrahydroindolo [2, 3-a] carbazole derivatives. *II Farmaco*. 2001;56(3):229-232.
93. Filitis L, Fedotova O, Akalaeva T, Bokanov A, Ivanov PY, Neustroeva V, Nyrkova V, Pershin G, Shvedov V. Synthesis and antitubercular activity *in vitro* of tetrahydrocarbazole derivatives. I. N-substituted hexahydro-1H-pyrazino [3, 2, 1-j, k] carbazoles. *Pharmaceutical Chemistry Journal*. 1986;20(3):185-188.
94. Kantevari S, Yempala T, Surineni G, Sridhar B, Yogeeswari P, Sriram D. Synthesis and antitubercular evaluation of novel dibenzo [b, d] furan and 9-methyl-9H-carbazole derived hexahydro-2H-pyrano [3, 2-c] quinolines via Povarov reaction. *European Journal of Medicinal Chemistry*. 2011;46(10):4827-4833.
95. Chirke SS, Krishna JS, Rathod BB, Bonam SR, Khedkar VM, Rao BV, Kumar S, Mahabalarao H, Shetty PR. Synthesis of Triazole Derivatives of 9-Ethyl-9H-carbazole and Dibenzo [b, d] furan and Evaluation of Their Antimycobacterial and Immunomodulatory Activity. *Chemistry Select*. 2017;2(24):7309-7318.
96. Choi TA, Czerwonka R, Fröhner W, Krahl MP, Reddy KR, Franzblau SG, Knölker HJ. Synthesis and activity of carbazole derivatives against *Mycobacterium tuberculosis*. *ChemMedChem*. 2006;1(8):812-815.
97. Satheeshkumar S, Amer HA, Hojjat Ghasemi G, Gopal N, Shushil Kumar S. Preliminary Studies on Ligand-based Design and Evaluation of New Mycobacterial ATP Synthase Inhibitors. *Current Drug Therapy*. 2017;12:1-18.
98. Scalacci N, Brown AK, Pavan FR, Ribeiro CM, Manetti F, Bhakta S, Maitra A, Smith DL, Petricci E, Castagnolo D. Synthesis and SAR evaluation of novel thioridazine derivatives active against drug-resistant tuberculosis. *European Journal of Medicinal Chemistry*. 2017;127:147-158.
99. Kinjo T, Koseki Y, Kobayashi M, Yamada A, Morita K, Yamaguchi K, Tsurusawa R, Gulten G, Komatsu H, Sakamoto H. Identification of compounds with potential antibacterial activity against *Mycobacterium* through structure-based drug screening. *Journal of chemical information and modeling*. 2013;53(5):1200-1212.
100. Santana M, Ionescu MS, Vertes A, Longin R, Kunst F, Danchin A, Glaser P. *Bacillus subtilis* F0F1 ATPase: DNA sequence of the atp operon and characterization of atp mutants. *Journal of bacteriology*. 1994;176(22):6802-6811.
101. Andries K, Verhasselt P, Guillemont J, Göhlmann HW, Neefs J-M, Winkler H, Van Gestel J, Timmerman P, Zhu M, Lee E. A diarylquinoline drug active on the ATP synthase of *Mycobacterium tuberculosis*. *Science*. 2005;307(5707):223-227.
102. Koul A, Vranckx L, Dendouga N, Balemans W, Van den Wyngaert I, Vergauwen K, Göhlmann HW, Willebrords R, Poncelet A, Guillemont J. Diarylquinolines are bactericidal for dormant mycobacteria as a result of disturbed ATP homeostasis. *Journal of Biological Chemistry*. 2008;283(37):25273-25280.
103. Cook GM, Hards K, Vilchèze C, Hartman T, Berney M. Energetics of respiration and oxidative phosphorylation in mycobacteria. *Microbiology spectrum*. 2014;2(3). 10.1128/microbiolspec.MGM2-0015-2013.
104. Cox RA, Cook GM. Growth regulation in the mycobacterial cell. *Current molecular medicine*. 2007;7(3):231-245.

105. Rao SP, Alonso S, Rand L, Dick T, Pethe K. The protonmotive force is required for maintaining ATP homeostasis and viability of hypoxic, nonreplicating *Mycobacterium tuberculosis*. *Proceedings of the National Academy of Sciences*. 2008;105(33):11945-11950.
106. Teh JS, Yano T, Rubin H. Type II NADH: menaquinone oxidoreductase of *Mycobacterium tuberculosis*. *Infectious Disorders Drug Targets*. 2007;7(2):169-181.
107. Fisher N, Bray PG, Ward SA, Biagini GA. The malaria parasite type II NADH: quinone oxidoreductase: an alternative enzyme for an alternative lifestyle. *Trends in parasitology*. 2007;23(7):305-310.
108. Fang J, Beattie DS. Novel FMN-containing rotenone-insensitive NADH dehydrogenase from *Trypanosoma brucei* mitochondria: isolation and characterization. *Biochemistry*. 2002;41(9):3065-3072.
109. Heikal A, Nakatani Y, Dunn E, Weimar MR, Day CL, Baker EN, Lott JS, Sazanov LA, Cook GM. Structure of the bacterial type II NADH dehydrogenase: a monotopic membrane protein with an essential role in energy generation. *Molecular microbiology*. 2014;91(5):950-964.
110. Sena FV, Batista AP, Catarino T, Brito JA, Archer M, Viertler M, Madl T, Cabrita EJ, Pereira MM. Type-II NADH: quinone oxidoreductase from *Staphylococcus aureus* has two distinct binding sites and is rate limited by quinone reduction. *Molecular microbiology*. 2015;98(2):272-288.
111. He C-X, Meng H, Zhang X, Cui H-Q, Yin D-L. Synthesis and bio-evaluation of phenothiazine derivatives as new anti-tuberculosis agents. *Chinese Chemical Letters*. 2015;26(8):951-954.
112. Bourdon J. Contribution to the study of the antibiotic properties of chlorpromazine or 4560 RP. *Ann Inst Pasteur (Paris)*. 1961;101:876-886.
113. Kamińska M. Role of chlorpromazine in the treatment of pulmonary tuberculosis in psychiatric patients. *Folia Medica Cracoviensia*. 1966;9(1):115-143.
114. Amaral L, Martins A, Molnar J, Kristiansen JE, Martins M, Viveiros M, Rodrigues L, Spengler G, Couto I, Ramos J. Phenothiazines, bacterial efflux pumps and targeting the macrophage for enhanced killing of intracellular XDR-TB. *In vivo*. 2010;24(4):409-424.
115. Amaral L, Molnar J. Potential therapy of multidrug-resistant and extremely drug-resistant tuberculosis with thioridazine. *In vivo*. 2012;26(2):231-236.
116. Amaral L, Kristiansen JE, Viveiros M, Atouguia J. Activity of phenothiazines against antibiotic-resistant *Mycobacterium tuberculosis*: a review supporting further studies that may elucidate the potential use of thioridazine as anti-tuberculosis therapy. *Journal of Antimicrobial Chemotherapy*. 2001;47(5):505-511.
117. Gadre D, Talwar V, Gupta H, Murthy R. Effect of trifluoperazine, a potential drug for tuberculosis with psychotic disorders, on the growth of clinical isolates of drug resistant *Mycobacterium tuberculosis*. *International clinical psychopharmacology*. 1998;13(3):129-132.
118. Crowle A, Douvas G, May M. Chlorpromazine: a drug potentially useful for treating mycobacterial infections. *Chemotherapy*. 1992;38(6):410-419.
119. Reddy MV, Nadadhur G, Gangadharam P. *In-vitro* and intracellular antimycobacterial activity of trifluoperazine. *Journal of Antimicrobial Chemotherapy*. 1996;37(1):196-197.

120. Katoch VM, Saxena N, Shivannavar CT, Sharma VD, Katoch K, Sharma RK, Murthy PS. Effect of trifluoperazine on *in vitro* ATP synthesis by *Mycobacterium leprae*. *FEMS Immunology & Medical Microbiology*. 1998;20(2):99-102.
121. Van Soolingen D, Hernandez-Pando R, Orozco H, Aguilar D, Magis-Escurra C, Amaral L, Van Ingen J, Boeree MJ. The antipsychotic thioridazine shows promising therapeutic activity in a mouse model of multidrug-resistant tuberculosis. *PLoS ONE*. 2010;5(9):e12640.
122. Weinstein EA, Yano T, Li L-S, Avarbock D, Avarbock A, Helm D, McColm AA, Duncan K, Lonsdale JT, Rubin H. Inhibitors of type II NADH:menaquinone oxidoreductase represent a class of antitubercular drugs. *Proceedings of the National Academy of Sciences of the United States of America*. 2005;102(12):4548-4553.
123. Fisher N, Warman AJ, Ward SA, Biagini GA. Type II NADH: Quinone Oxidoreductases of *Plasmodium Falciparum* and *Mycobacterium tuberculosis*: Kinetic and High-Throughput Assays. *Methods in enzymology*. 2009;456:303-320.
124. Amaral L, Viveiros M. Why thioridazine in combination with antibiotics cures extensively drug-resistant *Mycobacterium tuberculosis* infections. *International journal of antimicrobial agents*. 2012;39(5):376-380.
125. Amaral L, Martins M, Viveiros M, Molnar J, Kristiansen JE. Promising therapy of XDR-TB/MDR-TB with thioridazine an inhibitor of bacterial efflux pumps. *Current drug targets*. 2008;9(9):816-819.
126. Weinstein EA, Yano T, Li L-S, Avarbock D, Avarbock A, Helm D, McColm AA, Duncan K, Lonsdale JT, Rubin H. Inhibitors of type II NADH:menaquinone oxidoreductase represent a class of antitubercular drugs. *Proceedings of the National Academy of Sciences of the United States of America*. 2005;102(12):4548-4553.
127. Bate AB, Kalin JH, Fooksman EM, Amorose EL, Price CM, Williams HM, Rodig MJ, Mitchell MO, Cho SH, Wang Y. Synthesis and antitubercular activity of quaternized promazine and promethazine derivatives. *Bioorganic & Medicinal Chemistry Letters*. 2007;17(5):1346-1348.
128. Schurig-Briccio LA, Yano T, Rubin H, Gennis RB. Characterization of the Type 2 NADH:menaquinone oxidoreductases from *Staphylococcus aureus* and the bactericidal action of phenothiazines. *Biochimica et biophysica acta*. 2014;1837(7):954-963.
129. Dunn EA, Roxburgh M, Larsen L, Smith RA, McLellan AD, Heikal A, Murphy MP, Cook GM. Incorporation of triphenylphosphonium functionality improves the inhibitory properties of phenothiazine derivatives in *Mycobacterium tuberculosis*. *Bioorganic & Medicinal Chemistry*. 2014;22(19):5320-5328.
130. Walker JE. The ATP synthase: the understood, the uncertain and the unknown. *Biochemical Society Transactions*. 2013;41(1):1-16.
131. Boyer PD. The ATP synthase-a splendid molecular machine. *Annual review of biochemistry*. 1997;66(1):717-749.
132. Noji H, Yasuda R, Yoshida M, Kinosita Jr K. Direct observation of the rotation of F1-ATPase. *Nature*. 1997;386(6622):299-302.
133. Haagsma AC, Abdillahi-Ibrahim R, Wagner MJ, Krab K, Vergauwen K, Guillemont J, Andries K, Lill H, Koul A, Bald D. Selectivity of TMC207 towards mycobacterial ATP synthase compared with that towards the

- eukaryotic homologue. *Antimicrobial agents and chemotherapy*. 2009;53(3):1290-1292.
134. Gomez JE, McKinney JD. *M. tuberculosis* persistence, latency, and drug tolerance. *Tuberculosis*. 2004;84(1):29-44.
135. Bald D, Koul A. Respiratory ATP synthesis: the new generation of mycobacterial drug targets? *FEMS microbiology letters*. 2010;308(1):1-7.
136. Bald D, Koul A. Advances and strategies in discovery of new antibacterials for combating metabolically resting bacteria. *Drug discovery today*. 2013;18(5):250-255.
137. Cosma CL, Sherman DR, Ramakrishnan L. The secret lives of the pathogenic mycobacteria. *Annual Reviews in Microbiology*. 2003;57(1):641-676.
138. Koul A, Arnoult E, Lounis N, Guillemont J, Andries K. The challenge of new drug discovery for tuberculosis. *Nature*. 2011;469(7331):483-490.
139. Wayne LG, Sohaskey CD. Nonreplicating Persistence of *Mycobacterium tuberculosis*. *Annual Reviews in Microbiology*. 2001;55(1):139-163.
140. Timm J, Post FA, Bekker L-G, Walther GB, Wainwright HC, Manganelli R, Chan W-T, Tsenova L, Gold B, Smith I. Differential expression of iron-, carbon-, and oxygen-responsive mycobacterial genes in the lungs of chronically infected mice and tuberculosis patients. *Proceedings of the National Academy of Sciences*. 2003;100(24):14321-14326.
141. Berney M, Cook GM. Unique flexibility in energy metabolism allows mycobacteria to combat starvation and hypoxia. *PLoS ONE*. 2010;5(1):e8614.
142. Vesenbeckh S, Krieger D, Bettermann G, Schönfeld N, Bauer TT, Rüssmann H, Mauch H. Neuroleptic drugs in the treatment of tuberculosis: Minimal inhibitory concentrations of different phenothiazines against *Mycobacterium tuberculosis*. *Tuberculosis*. 2016;98:27-29.
143. Maitra A, Bates S, Kolvekar T, Devarajan PV, Guzman JD, Bhakta S. Repurposing-a ray of hope in tackling extensively drug resistance in tuberculosis. *International Journal of Infectious Diseases*. 2015;32:50-55.
144. Amaral L, Boeree MJ, Gillespie SH, Udwardia ZF, Van Soolingen D. Thioridazine cures extensively drug-resistant tuberculosis (XDR-TB) and the need for global trials is now! *International journal of antimicrobial agents*. 2010;35(6):524-526.
145. Krishna KM, Inturi B, Pujar GV, Purohit MN, Vijaykumar G. Design, synthesis and 3D-QSAR studies of new diphenylamine containing 1, 2, 4-triazoles as potential antitubercular agents. *European Journal of Medicinal Chemistry*. 2014;84:516-529.
146. Ma C, Case RJ, Wang Y, Zhang H-J, Tan GT, Van Hung N, Cuong NM, Franzblau SG, Soejarto DD, Fong HHS, Pauli GF. Anti-Tuberculosis Constituents from the Stem Bark of *Micromelum hirsutum*. *Planta Medica*. 2005;71(3):261-267.
147. Maghrabi AH, McGuffin LJ. ModFOLD6: an accurate web server for the global and local quality estimation of 3D protein models. *Nucleic Acids Research*. 2017:gkx332.
148. McGuffin LJ, Buenavista MT, Roche DB. The ModFOLD4 server for the quality assessment of 3D protein models. *Nucleic Acids Research*. 2013;41(W1):W368-W72.
149. Eisenberg D, Lüthy R, Bowie JU. [20] VERIFY3D: Assessment of protein models with three-dimensional profiles. *Methods in enzymology*. 1997;277:396-404.

150. Lovell SC, Davis IW, Arendall WB, de Bakker PI, Word JM, Prisant MG, Richardson JS, Richardson DC. Structure validation by C α geometry: ϕ , ψ and C β deviation. *Proteins: Structure, Function, and Bioinformatics*. 2003; 50 (3): 437-450.
151. Laskowski RA, MacArthur MW, Moss DS, Thornton JM. PROCHECK: a program to check the stereochemical quality of protein structures. *Journal of applied crystallography*. 1993;26(2):283-291.
152. Colovos C, Yeates TO. Verification of protein structures: patterns of nonbonded atomic interactions. *Protein science*. 1993;2(9):1511-1519.
153. Shen J, Zhang W, Fang H, Perkins R, Tong W, Hong H. Homology modeling, molecular docking, and molecular dynamics simulations elucidated α -fetoprotein binding modes. *BMC bioinformatics*. 2013;14(14):S6.
154. Kitchen DB, Decornez H, Furr JR, Bajorath J. Docking and scoring in virtual screening for drug discovery: methods and applications. *Nature reviews Drug discovery*. 2004;3(11):935-949.
155. Irwin JJ, Shoichet BK. ZINC-a free database of commercially available compounds for virtual screening. *Journal of chemical information and modeling*. 2005;45(1):177-182.
156. Styczynski MP, Jensen KL, Rigoutsos I, Stephanopoulos G. BLOSUM62 miscalculations improve search performance. *Nature Biotechnology*. 2008;26(3):274-275.
157. Preiss L, Langer JD, Yildiz Ö, Eckhardt-Strelau L, Guillemont JE, Koul A, Meier T. Structure of the mycobacterial ATP synthase Fo rotor ring in complex with the anti-TB drug bedaquiline. *Science Advances*. 2015;1(4):e1500106.
158. Lu P, Lill H, Bald D. ATP synthase in mycobacteria: special features and implications for a function as drug target. *Biochimica et Biophysica Acta (BBA)-Bioenergetics*. 2014;1837(7):1208-1218.
159. Friesner RA, Banks JL, Murphy RB, Halgren TA, Klicic JJ, Mainz DT, Repasky MP, Knoll EH, Shelley M, Perry JK. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. *Journal of medicinal chemistry*. 2004;47(7):1739-1749.
160. Sander T, Freyss J, von Korff M, Reich JR, Rufener C. OSIRIS, an entirely in-house developed drug discovery informatics system. *Journal of chemical information and modeling*. 2009;49(2):232-246.
161. Blaza JN, Bridges HR, Aragão D, Dunn EA, Heikal A, Cook GM, Nakatani Y, Hirst J. The mechanism of catalysis by type-II NADH: quinone oxidoreductases. *Scientific reports*. 2017;7:40165.
162. Koul A, Dendouga N, Vergauwen K, Molenberghs B, Vranckx L, Willebrords R, Ristic Z, Lill H, Dorange I, Guillemont J. Diarylquinolines target subunit c of mycobacterial ATP synthase. *Nature chemical biology*. 2007;3(6):323-324.
163. Haagsma AC, Driessen NN, Hahn M-M, Lill H, Bald D. ATP synthase in slow- and fast-growing mycobacteria is active in ATP synthesis and blocked in ATP hydrolysis direction. *FEMS microbiology letters*. 2010;313(1):68-74.
164. Lu P, Heineke MH, Koul A, Andries K, Cook GM, Lill H, Van Spanning R, Bald D. The cytochrome bd-type quinol oxidase is important for survival of *Mycobacterium smegmatis* under peroxide and antibiotic-induced stress. *Scientific reports*. 2015;5:10333.
165. Lourenço MC, de Souza MV, Pinheiro AC, Ferreira MdL, Gonçalves RS, Nogueira TCM, Peralta MA. Evaluation of anti-tubercular activity of nicotinic and isoniazid analogues. *Arkivoc*. 2007;15:181-91.

166. Bharti SK, Nath G, Tilak R, Singh S. Synthesis, anti-bacterial and anti-fungal activities of some novel Schiff bases containing 2, 4-disubstituted thiazole ring. *European Journal of Medicinal Chemistry*. 2010;45(2):651-660.